

A disease caused by activated oxygen, comprising administering to a mammal in need thereof a pharmaceutically effective, non-toxic dose of a peptide comprising the amino acid sequence consisting essentially of amino acid numbers 1 to 526 of SEQ ID NO: 12, and which catalyzes the reduction of dichloroindophenol and oxidized glutathione.

63. (Amended) A method for the prophylaxis or treatment of arteriosclerosis, diabetes, ischemic disorders, edema, vascular hyperpermeability, inflammation, gastric mucosa disorders, acute pancreatitis, Crohn's disease, ulcerative colitis, liver disorders, Paraquat's disease, pulmonary emphysema, chemocarcinogenesis, carcinogenic metastasis, adult respiratory distress syndrome, disseminated intravascular coagulation, cataracts, premature retinopathy, auto-immune diseases, porphyremia, hemolytic diseases, Mediterranean anemia, Parkinson's disease, Alzheimer's disease, epilepsy, ultraviolet radiation disorders, radioactive disorders, frostbite or burns, comprising administering to a mammal in need thereof a pharmaceutically effective, non-toxic dose of a peptide which comprises the amino acid sequence consisting essentially of amino acid numbers 1 to 526 of SEQ ID NO: 12, and which catalyzes the reduction of dichloroindophenol and oxidized glutathione.

71. (Amended) An antibody which specifically recognizes
KM31-7 protein.

73. (Amended) The antibody of claim 71, wherein said
antibody is humanized.

77. (Amended) A process for the purification of KM31-7
protein comprising contacting the antibody of claim 71 with a
suspension containing KM31-7 protein to bind said protein.

80. (Amended) A polypeptide comprising the sequence
consisting essentially of residues 4 to 437 of SEQ ID NO: 2.

Please cancel claims 1 to 47, 49 to 54, 56 to 59, 62, 64 to
70, 76 and 81 to 88, without prejudice.

Please add the following claims:

-- 89. (New) The method of claim 63, wherein the method is
for the prophylaxis of arteriosclerosis, diabetes or ischemic
disorders.

90. (New) The method of claim 63, wherein the method is for
the treatment of arteriosclerosis, diabetes or ischemic
disorders.--